Editorial: immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects (original) (raw)

Tulunay Virlan, Aysin ORCID logoORCID: https://orcid.org/0000-0003-4735-9902, Cafaro, Giacomo, Sunzini, Flavia, Degboe, Yannick and Christodoulou, Maria-Ionna(2024) Editorial: immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects.Frontiers in Oncology, 14, 1476475. (doi: 10.3389/fonc.2024.1476475) (PMID:39252949) (PMCID:PMC11381221)

Abstract

No abstract available.

Item Type: Articles (Editorial)
Keywords: Cancer immunotherapy, immune-checkpoint inhibitors (ICIs), immune-related adverse events (irAEs), autoimmunity, anti-CTLA-4, anti-PD-1/PD-L1.
Status: Published
Refereed: Yes
Glasgow Author(s) Enlighten ID: Christodoulou, Dr Maria-Ionna and Sunzini, Miss Flavia and Tulunay Virlan, Dr Aysin
Creator Roles: Tulunay Virlan, A.Writing – review and editingSunzini, F.Writing – review and editingChristodoulou, M.-I.Writing – original draft, Writing – review and editing
Authors: Tulunay Virlan, A., Cafaro, G., Sunzini, F., Degboe, Y., and Christodoulou, M.-I.
College/School: College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name: Frontiers in Oncology
Publisher: Frontiers Media
ISSN: 2234-943X
ISSN (Online): 2234-943X
Published Online: 26 August 2024
Copyright Holders: Copyright © 2024 Tulunay Virlan, Cafaro, Sunzini, Degboe and Christodoulou
First Published: First published in Frontiers in Oncology 14:1476475
Publisher Policy: Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details

ID Code: 361769
Depositing User: Dr Aysin Tulunay Virlan
Datestamp: 08 Aug 2025 11:26
Last Modified: 09 Aug 2025 01:31
Date of acceptance: 12 August 2024
Date of first online publication: 26 August 2024
Date Deposited: 8 August 2025
Data Availability Statement: No